• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Show Search
Home
EN / FR
  • LinkedIn
  • Twitter
Celyad Oncology

Celyad Oncology

  • About Us
    • Overview
    • Management Team
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • TIM
      • shRNA
      • shARC Platform
    • Manufacturing
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us
Home / Investors

Investors

Investors

Corporate Profile

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of CAR T therapies for cancer. The Company is developing a pipeline of allogeneic and autologous CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors.

NASDAQ EURONEXT Stock Information
Financial Market Data powered by Quotemedia. All rights reserved.
View the Terms of Use. Data delayed 15 minutes unless indicated.
ISIN: BE0974260896-XBRU Updated at
See Price Chart

Financial Calendar

March 24, 2022

FY 2021 Financial Results

May 5, 2022

Q1 2022 Financial Results

August 5, 2022

H1 2022 Financial Results

Nov 10, 2022

Q3 2022 Financial Results

Investors Kit

Corporate Presentation

Corporate Fact Sheet

Annual Report 2021

Upcoming Events

5

Aug
2022

First Half 2022 Financial Results

See More Events

Latest Financial News

6

May
2022

Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights

24

Mar
2022

Full Year 2021 Annual Report & Business Highlights

24

Mar
2022

Annual Report 2021

discover all Financial News

Footer

Celyad Oncology Logo
  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.
Cookie Policy | Privacy Policy | Terms of Use